Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

News Release

Printer Friendly Version View printer-friendly version
<< Back
Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting

PARSIPPANY, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chairman and chief executive officer, will testify this afternoon before President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis. The Commission, led by New Jersey Governor Chris Christie, was created to study ways to combat and treat drug abuse, addiction and the opioid crisis.

The meeting, which will be held in Washington, D.C. today from 12:30 p.m. until approximately 2:30 p.m. EDT, will consist of statements to the Commission from invited government, nonprofit, and business organizations regarding Innovative Pain Management and Prevention Measures for Diversion. Discussion related to the issues raised during the invited statements will follow.

Stack will discuss the critical nature of clinician and patient access to non-opioid medications that can effectively manage postsurgical pain while reducing opioid requirements. This is especially important in light of the opioid epidemic, as research continues to demonstrate a link between opioid overprescribing in the surgical setting and the risks of long-term use and/or accumulation of excess medication in the home, creating a dangerous potential for diversion or misuse.

Today’s meeting is the third in a series of meetings of the President's Commission on Combating Drug Addiction and the Opioid Crisis. It will be open to the public through live streaming on https://www.whitehouse.gov/live.

About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

Company Contact:
Pacira Pharmaceuticals, Inc.
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
aschneider@coynepr.com

Primary Logo

Pacira Pharmaceuticals, Inc

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...